PL
MRTX

Polianta Ltd’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Polianta Ltd’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,600
Closed -$737K – 104
2020
Q1 		$737K Buy
+9,600
New +$861K 0.51% 56

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Polianta Ltd's MRTX Position: Q2 2020 in Review

Polianta Ltd sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2020, closing a stake of 9,600 shares — an estimated $737K sold.

Polianta Ltd first reported a position in MRTX in Q1 2020 and held it in 1 quarter. The position peaked at $737K in Q1 2020. 200 funds tracked by Wall St. Rank hold MRTX as of Q2 2020.

  • Polianta Ltd reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Polianta Ltd sold 9,600 Mirati Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $737K.
  • Polianta Ltd first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Polianta Ltd's Mirati Therapeutics, Inc. Common Stock position peaked at $737K in Q1 2020.
  • 200 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Polianta Ltd's 13F filing for Q2 2020, filed 9 Jul 2020.